The aim of this study was to determine the impact of CPM on 20-year overall and disease-free survival and quality-adjusted life expectancy for women without a BRCA1/2 mutation, taking into consideration age at diagnosis, disease stage, ER status, and degree of family history of breast cancer. Here, BRCA1 is linked to breast carcinoma.